Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.

Takeda T, Yamamoto H, Kanzaki H, Suzawa K, Yoshioka T, Tomida S, Cui X, Murali R, Namba K, Sato H, Torigoe H, Watanabe M, Shien K, Soh J, Asano H, Tsukuda K, Kitamura Y, Miyoshi S, Sendo T, Toyooka S.

PLoS One. 2017 Feb 3;12(2):e0171356. doi: 10.1371/journal.pone.0171356. eCollection 2017. Erratum in: PLoS One. 2017 Mar 16;12 (3):e0174493.

2.

The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.

Hsu JL, Hung MC.

Cancer Metastasis Rev. 2016 Dec;35(4):575-588. doi: 10.1007/s10555-016-9649-6.

PMID:
27913999
3.

Quantitative diagnosis of HER2 protein expressing breast cancer by single-particle quantum dot imaging.

Miyashita M, Gonda K, Tada H, Watanabe M, Kitamura N, Kamei T, Sasano H, Ishida T, Ohuchi N.

Cancer Med. 2016 Oct;5(10):2813-2824. doi: 10.1002/cam4.898. Epub 2016 Sep 26.

4.

Overcoming resistance to HER2 inhibitors through state-specific kinase binding.

Novotny CJ, Pollari S, Park JH, Lemmon MA, Shen W, Shokat KM.

Nat Chem Biol. 2016 Nov;12(11):923-930. doi: 10.1038/nchembio.2171. Epub 2016 Sep 5.

5.

HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.

Xu QQ, Pan B, Wang CJ, Zhou YD, Mao F, Lin Y, Guan JH, Shen SJ, Zhang XH, Xu YL, Zhong Y, Wang XJ, Zhang YN, Sun Q.

Oncotarget. 2016 Sep 27;7(39):63571-63582. doi: 10.18632/oncotarget.11541.

6.

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine.

Recondo G Jr, de la Vega M, Galanternik F, Díaz-Cantón E, Leone BA, Leone JP.

Cancer Manag Res. 2016 May 19;8:57-65. doi: 10.2147/CMAR.S104447. eCollection 2016. Review.

7.

Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk.

Tamaskovic R, Schwill M, Nagy-Davidescu G, Jost C, Schaefer DC, Verdurmen WP, Schaefer JV, Honegger A, Plückthun A.

Nat Commun. 2016 Jun 3;7:11672. doi: 10.1038/ncomms11672.

8.

Integrated and Functional Genomics Analysis Validates the Relevance of the Nuclear Variant ErbB380kDa in Prostate Cancer Progression.

El Maassarani M, Barbarin A, Fromont G, Kaissi O, Lebbe M, Vannier B, Moussa A, Séité P.

PLoS One. 2016 May 18;11(5):e0155950. doi: 10.1371/journal.pone.0155950. eCollection 2016.

9.

ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation.

Nunes J, Zhang H, Angelopoulos N, Chhetri J, Osipo C, Grothey A, Stebbing J, Giamas G.

Oncotarget. 2016 May 10;7(19):27599-612. doi: 10.18632/oncotarget.8504.

10.

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It.

Luque-Cabal M, García-Teijido P, Fernández-Pérez Y, Sánchez-Lorenzo L, Palacio-Vázquez I.

Clin Med Insights Oncol. 2016 Mar 28;10(Suppl 1):21-30. doi: 10.4137/CMO.S34537. eCollection 2016. Review.

11.

Therapeutic siRNA for drug-resistant HER2-positive breast cancer.

Gu S, Hu Z, Ngamcherdtrakul W, Castro DJ, Morry J, Reda MM, Gray JW, Yantasee W.

Oncotarget. 2016 Mar 22;7(12):14727-41. doi: 10.18632/oncotarget.7409.

12.

Trastuzumab-Resistant Luminal B Breast Cancer Cells Show Basal-Like Cell Growth Features Through NF-κB-Activation.

Kanzaki H, Mukhopadhya NK, Cui X, Ramanujan VK, Murali R.

Monoclon Antib Immunodiagn Immunother. 2016 Feb;35(1):1-11. doi: 10.1089/mab.2015.0056. Epub 2016 Jan 21.

13.

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.

de Melo Gagliato D, Jardim DL, Marchesi MS, Hortobagyi GN.

Oncotarget. 2016 Sep 27;7(39):64431-64446. doi: 10.18632/oncotarget.7043. Review.

14.

Changing strategies for target therapy in gastric cancer.

Lee SY, Oh SC.

World J Gastroenterol. 2016 Jan 21;22(3):1179-89. doi: 10.3748/wjg.v22.i3.1179. Review.

15.

Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence.

Segovia-Mendoza M, González-González ME, Barrera D, Díaz L, García-Becerra R.

Am J Cancer Res. 2015 Aug 15;5(9):2531-61. eCollection 2015. Review.

16.

Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?

Graziano V, Scognamiglio MT, Zilli M, Giampietro J, Vici P, Natoli C, Grassadonia A.

Cancer Biol Ther. 2015;16(12):1704-9. doi: 10.1080/15384047.2015.1108490.

17.

Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.

Xu W, Bi Y, Zhang J, Kong J, Jiang H, Tian M, Li K, Wang B, Chen C, Song F, Pan X, Shi B, Kong X, Gu J, Cai X, Li Z.

Oncotarget. 2015 Nov 17;6(36):38840-53. doi: 10.18632/oncotarget.6111.

18.

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer.

Advani P, Cornell L, Chumsri S, Moreno-Aspitia A.

Breast Cancer (Dove Med Press). 2015 Sep 22;7:321-35. doi: 10.2147/BCTT.S90627. eCollection 2015. Review.

19.

Targeting HER2 Positive Breast Cancer with Chemopreventive Agents.

Wahler J, Suh N.

Curr Pharmacol Rep. 2015 Oct 1;1(5):324-335. Epub 2015 Apr 19.

20.

Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.

Park YH, Shin HT, Jung HH, Choi YL, Ahn T, Park K, Lee A, Do IG, Kim JY, Ahn JS, Park WY, Im YH.

Oncotarget. 2015 Oct 13;6(31):32027-38. doi: 10.18632/oncotarget.5184.

Supplemental Content

Support Center